United States: DOJ Backs Up Yates Memo With Indictment Of Former Warner Chilcott Executive

Michael Manthei is a Partner and Kristin Cleary an Associate in Holland & Knight's Boston office


  • A grand jury in the U.S. District Court for the District of Massachusetts has returned an indictment against W. Carl Reichel, a former president of Warner Chilcott PLC's pharmaceuticals division, for his alleged participation in a criminal conspiracy to pay kickbacks to physicians in exchange for prescribing Warner Chilcott drugs.
  • Additionally, in a global settlement agreement that resolved Warner Chilcott's criminal and civil liability for the illegal marketing of seven brand-name drugs between 2009 and 2013, the company agreed to pay $125 million and is permanently excluded from participating in federal healthcare programs, including Medicaid and Medicare.
  • The individual prosecution of Reichel is unusual and may signal a new trend in the Department of Justice's (DOJ) enforcement strategy following the Yates memo in September.

A grand jury in the U.S. District Court for the District of Massachusetts returned an indictment against W. Carl Reichel, a former president of Warner Chilcott PLC's pharmaceuticals division, on Oct. 28, 2015. A day later, he was arrested in Boston for his alleged participation in a criminal conspiracy to pay kickbacks to physicians in exchange for prescribing Warner Chilcott drugs. He pleaded not guilty and was released on personal recognizance.

Reichel's arrest was announced in conjunction with Warner Chilcott's global settlement agreement with the government. Resolving both criminal and civil liability for the company's illegal marketing of seven brand-name drugs between 2009 and 2013, the company agreed to pay $125 million. Of that amount, $22.94 million represents a criminal fine. Moreover, Warner Chilcott is permanently excluded from participating in federal healthcare programs, including Medicaid and Medicare. The drugs at issue are Actonel, Asacol, Atelvia, Doryx, Enablex, Estrace and Loestrin.

While announcements of multimillion-dollar settlements with pharmaceutical manufacturers are hardly noteworthy, the individual prosecution of Reichel is unusual and may signal a new trend in the Department of Justice's (DOJ) enforcement strategy following its Yates memo in September. The widely publicized and discussed policy pronouncement by Deputy Attorney General Sally Yates highlights the need to hold individuals accountable for corporate wrongdoing. With Reichel's arrest and the Warner Chilcott settlement, the DOJ reiterated its commitment to holding both "companies and responsible individuals accountable when they use improper incentives... to promote their products."

Reichel was not alone. Two former Warner Chilcott district sales managers pled guilty to conspiracy to commit healthcare fraud and violations of the Health Insurance Portability and Accountability Act (HIPAA). A third former district manager was charged criminally earlier in October, also for HIPAA violations in connection with allegedly inaccurate prior authorization forms. Lastly, Rita Luthra, a gynecologist in Springfield, Mass., is facing criminal charges for violating the Anti-Kickback Statute for accepting free meals and speaker fees from Warner Chilcott in return for prescribing the company's products. She is charged additionally with wrongfully disclosing individually identifiable health information and obstructing a criminal health care investigation.

Allegations Involving Warner Chilcott's Marketing Strategy

Reichel, along with a senior executive to whom he reported, allegedly developed Warner Chilcott's illegal marketing strategy. Reichel, in turn, was allegedly responsible for communicating the strategy to the sales force. Notably, all of the alleged kickbacks involve ubiquitous pharma marketing strategies. The thrust of the indictment appears to be that these programs were shams intended to disguise the payment of kickbacks in exchange for prescriptions of Warner Chilcott products.

  • Medication education programs: The government alleges that Reichel directed his sales force to treat doctors to dinner at expensive restaurants to "build relationships." In contrast to educational programs of other pharmaceutical manufacturers that educate physicians on the benefits and risks of the company's drugs, Warner Chilcott's so-called "med eds" allegedly had no clinical component, per Reichel's instruction. Moreover, doctors were encouraged to bring their spouse, increasing the social aspect of the dinner. The government alleges that sales reps would pressure the doctor to commit to prescribing Warner Chilcott products during dinner. If the physician was not writing enough prescriptions, the sales rep would then follow up to hold the doctor accountable for his or her commitment. Furthermore, sales reps allegedly left credit cards at expensive restaurants for physicians to have dinner on their own, without the sales rep being present. The government alleges that sales reps also provided doctors with gift cards worth several hundred dollars to expensive restaurants.
  • Speaker fees: The second prong of Reichel's sales strategy allegedly involved paying physicians to speak about the company's products. As with educational programming, pharmaceutical manufacturers often pay doctors to be speakers. Here, physicians were paid $600 to $1,200 to attend dinners, which the government alleges were nothing more than informal dinners without a clinical component. Reichel allegedly directed his sales force to use only those speakers that had "clinical experience" with the company's drugs, which was understood to mean that the doctors were actively prescribing Warner Chilcott products. According to the indictment, sales reps set market share thresholds for speakers. If a doctor was not performing, the sales rep would let the doctor know that he or she would no longer be paid as a speaker until prescriptions increased.
  • Prior authorization: According to the DOJ, the final component of Reichel's strategy involved obtaining insurance coverage for Warner Chilcott's drugs by allegedly submitting inaccurate prior authorization forms to insurance companies. Sales reps bought food and drink for the doctor's office staff. In exchange, the government alleges, the staff submitted prior authorization forms to insurers, seeking coverage of Warner Chilcott's more expensive osteoporosis drugs. Generally, cost-effective competitor drugs were preferred on Medicare Part D formularies. As a result, patients were required to obtain authorization from the insurance company for coverage of Warner Chilcott's more expensive drugs. According to the indictment, these requests used "canned" statements designed to obtain insurance coverage, without accurately reflecting the patient's condition.

Generally, Warner Chilcott's educational programs and speaker's bureau are not atypical compared to other manufacturers. From the indictment, it appears that the government views Warner Chilcott's marketing efforts as sham arrangements designed to funnel kickback payments to doctors. The "med eds," rather than educating healthcare professionals, were allegedly just social dinners without any clinical component. Similarly, the government alleges that Warner Chilcott's "speakers" often did not speak, but simply attended dinners at expensive restaurants. And the aggressive sales jargon detailed in the indictment, considered innocuous in other contexts, quickly becomes problematic from the government's perspective in the healthcare realm.

Recognizing that corporations can only act through individuals and that large corporate settlements have become the cost of doing business rather than a strong deterrent, the Yates memo reiterates and reinvigorates the DOJ's longstanding policy on charging individuals involved in corporate wrongdoing.

Holland & Knight will continue to monitor the prosecution of Reichel and the DOJ's implementation of the Yates memo.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.